BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 15 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 16 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 17 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 15 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 16 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 17 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT
AlphaGraphs

Infographic: Teva Pharmaceuticals (TEVA) Q1 2021 earnings results

Teva Pharmaceuticals’ (NYSE: TEVA) reported first-quarter 2021 results today before the opening bell. The company dropped its revenue by 9% to $3.98 billion year on year. The net income attributable to TEVA was $77 million or $0.07 per share compared to $69 million or $0.06 per share of the same quarter in the previous year.

$TEVA April 28, 2021 1 min read
NYSE
$TEVA · Earnings

Teva Pharmaceuticals’ (NYSE: TEVA) reported first-quarter 2021 results today before the opening bell. The company dropped its revenue by 9% to $3.98 billion year on year. The net income attributable to TEVA was $77 million or $0.07 per share compared to $69 million or $0.06 per share of the same quarter in the previous year.

· April 28, 2021

Teva Pharmaceuticals’ (NYSE: TEVA) reported first-quarter 2021 results today before the opening bell.

The company dropped its revenue by 9% to $3.98 billion year on year.

The net income attributable to TEVA was $77 million or $0.07 per share compared to $69 million or $0.06 per share of the same quarter in the previous year.

  • Teva Pharmaceuticals (TEVA) Q2 2020 Earnings Infograph
  • Teva Pharmaceuticals (TEVA) Q1 2020 Earnings Infograph

ADVERTISEMENT